<DOC>
	<DOCNO>NCT00930475</DOCNO>
	<brief_summary>This open-label , mono-center phase I/II study design determine maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) RAD001 combination carboplatin taxane- anthracycline-pretreated patient progressive metastatic breast cancer . Additionally , study design characterize safety , tolerability efficacy study .</brief_summary>
	<brief_title>Everolimus ( RAD001 ) Carboplatin Pretreated Metastatic Breast Cancer</brief_title>
	<detailed_description>During phase I part study include least 3 patient dose-level MTD reach . Each cohort consist newly enrol patient . Intra-patient dose escalation permit . Once MTD reach total 6 patient treat MTD ( phase I ) . For phase II minimax two-stage design apply . After test drug 16 patient first stage phase II , trial terminate 1 few respond ( SD , PR , CR ) . If trial go second stage , total 34 patient studied phase II part .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>adult female patient least two prior chemotherapy due metastatic inoperable breast cancer Karnofsky performance status least 60 % pretreatment least one taxane one anthracycline previous treatment mTORinhibitors , carboplatin , cisplatin oxaliplatin inadequate organ function include bone marrow function bleeding tumour know uncontrolled metastasis CNS carcinomatous meningosis patient treat last five day inhibitor inducer CYP3A serious pulmonary , neurological , endocrinological disorder interfere study medication , especially patient know lung fibrosis , emphysema severe COPD</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>